Clinical

Dataset Information

0

Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine


ABSTRACT: Unresectable metastatic colorectal cancer (mCRC) remains an incurable disease. After failure of conventional treatments involving fluoropyrimidines, oxaliplatin and irinotecan in combination or not with biotherapies targeting EGFR and VEGF; regorafenib shows a modest improvement in overall survival. Recently, trifluridine/tipiracil has also shown efficacy in phase 3 with an overall survival of around 7 months. Trifluridine/tipiracil has become the standard of care for advanced mCRC in most western countries. However, the objective response rate remains very low and the survival gain remains moderate (+2 months). Therefore, new strategies are needed to ensure that mCRC patients who have received multiple lines of therapy can receive more effective treatments. Based on previous clinical trials on IL-1 inhibition and our preclinical data, IL-1 inhibition may increase the efficacy of trifluridine/tipiracil. The goal is to test whether the addition of XB2001 to trifluridine/tipiracil could be synergistic.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2401722 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2366035 | ecrin-mdr-crc
| 2315052 | ecrin-mdr-crc
| 60837 | ecrin-mdr-crc
| 2386782 | ecrin-mdr-crc
| 2403437 | ecrin-mdr-crc
| S-EPMC8658167 | biostudies-literature
| 2352790 | ecrin-mdr-crc
| 2256144 | ecrin-mdr-crc
2017-09-25 | GSE96786 | GEO
2017-09-25 | GSE96785 | GEO